tetano
Editor, Senior Moderator
Immunity
. 2020 Nov 25;S1074-7613(20)30502-1.
doi: 10.1016/j.immuni.2020.11.015. Online ahead of print.
Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses
Xiancai Ma[SUP] 1 [/SUP], Fan Zou[SUP] 2 [/SUP], Fei Yu[SUP] 3 [/SUP], Rong Li[SUP] 1 [/SUP], Yaochang Yuan[SUP] 1 [/SUP], Yiwen Zhang[SUP] 1 [/SUP], Xiantao Zhang[SUP] 1 [/SUP], Jieyi Deng[SUP] 1 [/SUP], Tao Chen[SUP] 1 [/SUP], Zheng Song[SUP] 1 [/SUP], Yidan Qiao[SUP] 1 [/SUP], Yikang Zhan[SUP] 1 [/SUP], Jun Liu[SUP] 4 [/SUP], Junsong Zhang[SUP] 3 [/SUP], Xu Zhang[SUP] 1 [/SUP], Zhilin Peng[SUP] 1 [/SUP], Yuzhuang Li[SUP] 1 [/SUP], Yingtong Lin[SUP] 1 [/SUP], Liting Liang[SUP] 2 [/SUP], Guanwen Wang[SUP] 3 [/SUP], Yingshi Chen[SUP] 1 [/SUP], Qier Chen[SUP] 1 [/SUP], Ting Pan[SUP] 5 [/SUP], Xin He[SUP] 1 [/SUP], Hui Zhang[SUP] 6 [/SUP]
Affiliations
Abstract
Various vaccine strategies have been proposed in response to the global COVID-19 pandemic, each with unique strategies for eliciting immune responses. Here, we developed nanoparticle vaccines by covalently conjugating the self-assembled 24-mer ferritin to the receptor binding domain (RBD) and/or heptad repeat (HR) subunits of the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) spike (S) protein. Compared to monomer vaccines, nanoparticle vaccines elicited more robust neutralizing antibodies and cellular immune responses. RBD and RBD-HR nanoparticle vaccinated hACE2 transgenic mice vaccinated with RBD and/or RBD-HR nanoparticles exhibited reduced viral load in the lungs after SARS-CoV-2 challenge. RBD-HR nanoparticle vaccines also promoted neutralizing antibodies and cellular immune responses against other coronaviruses. The nanoparticle vaccination of rhesus macaques induced neutralizing antibodies, and T and B cell responses prior to boost immunization; these responses persisted for more than three months. RBD- and HR-based nanoparticles thus present a promising vaccination approach against SARS-CoV-2 and other coronaviruses.
Keywords: COVID-19; HR; RBD; SARS-CoV-2; nanoparticle vaccine.
. 2020 Nov 25;S1074-7613(20)30502-1.
doi: 10.1016/j.immuni.2020.11.015. Online ahead of print.
Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses
Xiancai Ma[SUP] 1 [/SUP], Fan Zou[SUP] 2 [/SUP], Fei Yu[SUP] 3 [/SUP], Rong Li[SUP] 1 [/SUP], Yaochang Yuan[SUP] 1 [/SUP], Yiwen Zhang[SUP] 1 [/SUP], Xiantao Zhang[SUP] 1 [/SUP], Jieyi Deng[SUP] 1 [/SUP], Tao Chen[SUP] 1 [/SUP], Zheng Song[SUP] 1 [/SUP], Yidan Qiao[SUP] 1 [/SUP], Yikang Zhan[SUP] 1 [/SUP], Jun Liu[SUP] 4 [/SUP], Junsong Zhang[SUP] 3 [/SUP], Xu Zhang[SUP] 1 [/SUP], Zhilin Peng[SUP] 1 [/SUP], Yuzhuang Li[SUP] 1 [/SUP], Yingtong Lin[SUP] 1 [/SUP], Liting Liang[SUP] 2 [/SUP], Guanwen Wang[SUP] 3 [/SUP], Yingshi Chen[SUP] 1 [/SUP], Qier Chen[SUP] 1 [/SUP], Ting Pan[SUP] 5 [/SUP], Xin He[SUP] 1 [/SUP], Hui Zhang[SUP] 6 [/SUP]
Affiliations
- PMID: 33275896
- DOI: 10.1016/j.immuni.2020.11.015
Abstract
Various vaccine strategies have been proposed in response to the global COVID-19 pandemic, each with unique strategies for eliciting immune responses. Here, we developed nanoparticle vaccines by covalently conjugating the self-assembled 24-mer ferritin to the receptor binding domain (RBD) and/or heptad repeat (HR) subunits of the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) spike (S) protein. Compared to monomer vaccines, nanoparticle vaccines elicited more robust neutralizing antibodies and cellular immune responses. RBD and RBD-HR nanoparticle vaccinated hACE2 transgenic mice vaccinated with RBD and/or RBD-HR nanoparticles exhibited reduced viral load in the lungs after SARS-CoV-2 challenge. RBD-HR nanoparticle vaccines also promoted neutralizing antibodies and cellular immune responses against other coronaviruses. The nanoparticle vaccination of rhesus macaques induced neutralizing antibodies, and T and B cell responses prior to boost immunization; these responses persisted for more than three months. RBD- and HR-based nanoparticles thus present a promising vaccination approach against SARS-CoV-2 and other coronaviruses.
Keywords: COVID-19; HR; RBD; SARS-CoV-2; nanoparticle vaccine.